Lineagen traces its roots directly to the formation of the Lineagen Research Corporation in 2002 by the State of Utah under then-Governor Michael O. Leavitt, specifically to commercialize Utah’s unique population genetic assets. These assets themselves trace their roots to the watershed Alta Summit of 1984, the advent of the Human Genome project and the springboard for Utah’s eventual position at the epicenter of discovery for practical, clinical applications of highly advanced genetic science. As a beneficiary of Utah’s unique genetic assets, and through its sponsored research and exclusive license relationship with the University of Utah, Lineagen evolved rapidly from its infancy as a research organization into a customer-focused, commercial diagnostics business with leading programs in autism spectrum disorder (ASD), multiple sclerosis (MS), and chronic obstructive pulmonary disease (COPD).

Today, with an executive team comprised of experienced entrepreneurs and former leaders of highly regarded specialty diagnostic firms such as Myriad Genetics, Genoptix, and others, Lineagen's team is expert in making highly advanced genetic science both relevant and accessible to the private clinical practice.